Regado Biosciences Inc

(RGDO) Trade

By |

Profile

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.

Contact Information

Website: www.tobiratherapeutics.com
Main Phone: +1 650 741-6625
Address: 701 Gateway Boulevard
Address 2: Suite 300
State: CA
City / Town: South San Francisco
Country: USA
Postal Code: 94080

Issuer Information

Exchange: NSD
CEO: Laurent Fischer
Employees: 20
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 3,734,353.00 EPS (TTM) N/A PE Ratio N/A Exchange NSD